A clinical trial has revealed that an experimental drug could offer ‘game-changing treatment for patients with aggressive brain cancers. Two out of ten patients who received the new precision drug, ipatasertib, in conjunction with the immunotherapy agent atezolizumab, observed that their cancer cells had stopped growing.
One of the patient’s tumour appeared to have disappeared completely. The Institute of Cancer Research, which led the research, said it was unusual to see positive responses so early in a trial.
Lead researcher Dr Juanita Lopez said: “We believe that our findings open the door to the further development of what could become a game-changing treatment option for some patients with aggressive glioblastoma brain cancer. Patients with glioblastoma have very poor survival rates… so any advance in outcomes would be extremely welcome.”
